Development and Validation of a Liquid Chromatograph–Tandem Mass Spectrometry Method for Quantifying Ganciclovir in Dried Blood Spots for Therapeutic Drug Monitoring
Biomedical Chromatography · 2026-04 · 40 (4)
DOI: 10.1002/bmc.70411 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 24.02.2026. Verfasst von Naoki Tamura und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Kobe University Hospital, Kobe, Japan. Hauptthemen laut MEDLINE: Ganciclovir, Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry, Drug Monitoring. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Valganciclovir (VGCV) is the first‐line drug for preemptive therapy of cytomegalovirus (CMV) infection. However, even at standard doses, plasma concentrations of the active metabolite ganciclovir (GCV) show substantial inter‐individual variability. To ensure therapeutic efficacy and minimize adverse effects, therapeutic drug monitoring (TDM) based on the area under the concentration–time curve (AUC) is essential. Yet, conventional TDM via venous blood sampling is invasive and unsuitable for frequent monitoring. In this study, we aimed to develop a simple and minimally invasive method for GCV quantification using dried blood spots (DBS) combined with liquid chromatography–tandem mass spectrometry (LC–MS/MS). The method demonstrated a good linearity over a concentration range of 0.25–16 μg/mL and satisfied the validation criteria for accuracy and precision. It showed acceptable stability for up to 7 days under refrigerated conditions. Methanol was identified as the optimal extraction solvent, allowing for a simplified sample pretreatment without the need for ultrasonic processing. While hematocrit levels affected spot size and quantification accuracy, reliable measurements were obtained within the 30%–50% hematocrit range. The established DBS‐based LC–MS/MS method provides a promising, minimally invasive approach for TDM of GCV in the management of CMV infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Kobe University Hospital, Kobe, Japan.
- Department of Pharmaceutical Technology, Kobe Pharmaceutical University, Kobe, Japan.
- Laboratory of Pharmacy Practice, Comprehensive Education and Research Center, Kobe Pharmaceutical University, Kobe, Japan.
- Department of Integrated Clinical and Basic Pharmaceutical Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
- Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.
ORCID-Profile: Kotaro Itohara
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Tamura, N., Itohara, K., Kouyama, S., Kitahiro, Y., Yamamoto, K., Omura, T., Sakane, T., Saegusa, J., & Yano, I. (2026). Development and Validation of a Liquid Chromatograph–Tandem Mass Spectrometry Method for Quantifying Ganciclovir in Dried Blood Spots for Therapeutic Drug Monitoring. Biomedical Chromatography, 40(4). https://doi.org/10.1002/bmc.70411
Vancouver
Tamura N, Itohara K, Kouyama S, Kitahiro Y, Yamamoto K, Omura T, et al. Development and Validation of a Liquid Chromatograph–Tandem Mass Spectrometry Method for Quantifying Ganciclovir in Dried Blood Spots for Therapeutic Drug Monitoring. Biomedical Chromatography. 2026;40(4). doi:10.1002/bmc.70411
BibTeX
@article{Tamura2026,
author = {Tamura, Naoki and Itohara, Kotaro and Kouyama, Suguru and Kitahiro, Yumi and Yamamoto, Kazuhiro and Omura, Tomohiro and Sakane, Toshiyasu and Saegusa, Jun and Yano, Ikuko},
title = {Development and Validation of a Liquid Chromatograph–Tandem Mass Spectrometry Method for Quantifying Ganciclovir in Dried Blood Spots for Therapeutic Drug Monitoring},
journal = {Biomedical Chromatography},
year = {2026},
volume = {40},
number = {4},
doi = {10.1002/bmc.70411}
}
EUVIMED